Trial Profile
Evaluation of amyloid burden assessed by Florbetapir F 18 in patients with major depressive disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2017
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Major depressive disorder
- Focus Diagnostic use
- 15 Mar 2017 New trial record